JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Tamibarotene (formerly SY-1425; SY1425; Am 80; Retinobenzoic acid, Amnoid, AMNOLAKE) is a novel, potent, orally bioavailable, and synthetic retinoic acid receptor (RAR) agonist with potential anticancer activity against AML-acute promyelocytic leukaemia. It has high specificity for RARalpha and RARbeta over RARgamma. Tamibarotene is developed to overcome all-trans retinoic acid (ATRA) resistance. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro.
References: Leukemia. 2005 Jun; 19(6):901-9; J Leukoc Biol. 2011 Aug; 90(2):235-47; Biol Pharm Bull. 2009 Jul; 32(7):1307-9.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!